Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AMG-706 Comparison To Avastin Is Critical To Commercial Success, Amgen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen reiterates need to compare the investigational oncologic to Avastin after changing its Phase III clinical program in April.

You may also be interested in...

Amgen Splits AMG-706/Avastin Head-To-Head NSCLC Study Into Two Trials

One trial will compare the multi-VEGF agent with Avastin in non-squamous non-small cell lung cancer and the second will study AMG-706’s effect in all non-small cell carcinoma patients.

Genentech Aims To Extend Avastin Duration Of Use

Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts